Aclaris Therapeutics Stock Price Prediction
| ACRS Stock | USD 1.22 0.02 1.61% |
Oversold Vs Overbought
46
Oversold | Overbought |
Aclaris Therapeutics stock price prediction is an act of determining the future value of Aclaris Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Aclaris Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Aclaris Therapeutics and does not consider all of the tangible or intangible factors available from Aclaris Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Aclaris Therapeutics, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Aclaris Therapeutics' stock price prediction:EPS Estimate Next Quarter (0.31) | EPS Estimate Current Year (0.99) | EPS Estimate Next Year (0.82) | Wall Street Target Price 1.8 | EPS Estimate Current Quarter (0.34) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Aclaris Therapeutics based on different types of headlines from major news networks to social media. The Aclaris stock price prediction module provides an analysis of price elasticity to changes in media outlook on Aclaris Therapeutics over a specific investment horizon. Using Aclaris Therapeutics hype-based prediction, you can estimate the value of Aclaris Therapeutics from the perspective of Aclaris Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Aclaris Therapeutics using Aclaris Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Aclaris using crowd psychology based on the activity and movement of Aclaris Therapeutics' stock price.
Aclaris Therapeutics Implied Volatility | 90.01 |
Aclaris Therapeutics' implied volatility exposes the market's sentiment of Aclaris Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Aclaris Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Aclaris Therapeutics stock will not fluctuate a lot when Aclaris Therapeutics' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Aclaris Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Aclaris Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Aclaris because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Aclaris Therapeutics after-hype prediction price | USD 1.24 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Aclaris |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aclaris Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aclaris Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Aclaris Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Aclaris Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Aclaris Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Aclaris Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Aclaris Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Aclaris Therapeutics' historical news coverage. Aclaris Therapeutics' after-hype downside and upside margins for the prediction period are 0.06 and 5.07, respectively. We have considered Aclaris Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Aclaris Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of Aclaris Therapeutics is based on 3 months time horizon.
Aclaris Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Aclaris Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aclaris Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Aclaris Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.02 | 3.86 | 0.00 | 0.01 | 8 Events / Month | 3 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.22 | 1.24 | 0.00 |
|
Aclaris Therapeutics Hype Timeline
Aclaris Therapeutics is presently traded for 1.22. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Aclaris is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is presently at 0.02%. %. The volatility of related hype on Aclaris Therapeutics is about 1255.28%, with the expected price after the next announcement by competition of 1.21. About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.55. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 1.27. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 8 days. Check out Aclaris Therapeutics Basic Forecasting Models to cross-verify your projections.Aclaris Therapeutics Related Hype Analysis
Having access to credible news sources related to Aclaris Therapeutics' direct competition is more important than ever and may enhance your ability to predict Aclaris Therapeutics' future price movements. Getting to know how Aclaris Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Aclaris Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SSIC | Silver Spike Investment | (0.32) | 9 per month | 1.41 | 0.18 | 4.64 | (2.50) | 11.33 | |
| ALKS | Alkermes Plc | (0.56) | 11 per month | 0.00 | (0.1) | 2.79 | (4.24) | 21.89 | |
| EGRX | Eagle Pharmaceuticals | (0.40) | 10 per month | 4.87 | 0.03 | 8.00 | (7.92) | 23.10 | |
| EVO | Evotec SE ADR | 0.05 | 3 per month | 0.00 | (0.1) | 4.10 | (4.16) | 13.79 |
Aclaris Therapeutics Additional Predictive Modules
Most predictive techniques to examine Aclaris price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Aclaris using various technical indicators. When you analyze Aclaris charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Aclaris Therapeutics Predictive Indicators
The successful prediction of Aclaris Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Aclaris Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Aclaris Therapeutics based on analysis of Aclaris Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Aclaris Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aclaris Therapeutics's related companies. | 2021 | 2023 | 2024 (projected) | Dividend Yield | 0.003787 | 0.004355 | 0.004138 | Price To Sales Ratio | 122.0 | 2.35 | 2.23 |
Story Coverage note for Aclaris Therapeutics
The number of cover stories for Aclaris Therapeutics depends on current market conditions and Aclaris Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Aclaris Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Aclaris Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Aclaris Therapeutics Short Properties
Aclaris Therapeutics' future price predictability will typically decrease when Aclaris Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Aclaris Therapeutics often depends not only on the future outlook of the potential Aclaris Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aclaris Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 69.8 M | |
| Cash And Short Term Investments | 119.1 M |
Check out Aclaris Therapeutics Basic Forecasting Models to cross-verify your projections. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.